You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Geriatric Symptom Protocols for Improved Triage in Offices and Assisted Living
SBC: KEONA HEALTH, INC. Topic: NINRDESCRIPTION (provided by applicant): For medical practices, a major challenge is managing the hundreds of telephone calls received daily, many of which are about new or worsening medical symptoms. Particularly difficult are calls from persons with little or no medical training about frail older persons living at home or in assisted living (AL) communities. Incoming calls are typically answered by ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Gene Therapy to Protect the Lung from Oxidant Stress
SBC: LEXEO Therapeutics LLC Topic: NHLBIAbstractThe focus of this proposal is the development of therapy to protect the lung with an extracellular anti oxidant defense to treat chronic obstructive pulmonary diseaseCOPDa chronic disorder in which inhaled oxidants from tobacco smokepollution and generated within the lung by activated inflammatory cells perpetuate injury to the lung epithelium and endotheliumThe LEXEO strategy is to use in ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Development and in vitro validation of therapy for mucopolysaccharidosis III
SBC: Phoenix Nest Inc. Topic: 105DESCRIPTION provided by applicant Sanfilippo disease mucopolysaccharidosis type III MPS III is a devastating neurodegenerative lysosomal storage disorder of childhood for which there is no cure or effective treatment available The fundamental cause of MPS III is an inherited mutation in one of the enzymes required to catabolize heparan sulfate HS a glycosaminoglycan which plays importa ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Using Structuring Interacting RNAs (sxRNAs) as microRNA Inhibitors
SBC: HocusLocus Inc. Topic: NIGMSDESCRIPTION (provided by applicant): We propose developing a trans-molecular RNA-switch for scientists to negatively affect the activity of endogenous microRNA for use as a molecular tool or therapeutic, an anti-miR. Since the discovery of miRNA, the creation of effective anti-miRs has been important, first to study and verify miRNA interactions, and, secondly, as a therapeutic tool. But, creating ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A novel asthma drug candidate targeting the GABAergic system in lung inflammation
SBC: PANTHERICS INCORPORATED Topic: NHLBIThe proposed research will advance preclinical characterization and validation of a novel drug for asthmaA growing body of research has uncovered functional gamma amino butyric acid type A receptorGABAARsignaling in non neuronal cellsOur research has demonstrated that ligands activating GABAAR subtypes located on airway smooth muscle and immune cells reduce airway hyper responsivenessAHRand inflam ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Image-guided planning system for skull correction in children with craniosynostos
SBC: KITWARE INC Topic: NICHDDESCRIPTION (provided by applicant): Craniosynostosis is the premature fusion of cranial sutures and occurs in approximately one in 2000 live births. It results in cranial malformation that can lead to elevated intra-cranial pressure, brain growth impairment, and developmental deficiency. The most common treatment option for craniosynostosis is surgery. Currently, surgical treatment planning of cr ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Optimizing membrane repair for the treatment of Duchenne muscular dystrophy
SBC: MYOFINITY BIOSCIENCES INC Topic: NIAMSPROJECT ABSTRACT The long term goal of this project is to optimize a protein therapeutic for Duchenne muscular dystrophyDMDand potentially other muscle diseasesthat will enhance the repair capacity of muscle cell membranes that are compromised by mutations in the dystrophin dystroglycan complexMutations in the dystrophin dystroglycan complex result in Duchenne muscular dystrophyMyos Incis developi ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics
SBC: PPI PHARMACEUTICALS, LLC Topic: NCIDESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Correction of Splicing Defects in Cystic Fibrosis with Peptide-Oligonucleotide Conjugates and Small Molecule Enhancing Compounds
SBC: Initos Pharmaceuticals LLC Topic: NCATSABSTRACT The pathogenesis of Cystic FibrosisCFis caused by mutations in the gene for CFTRa cAMP activated chloride channel that regulates salt and water transport in epithelial tissuesespecially those in the airwaysRecent progress has resulted in small molecule therapeutic agents that partially correct defects in the CFTR protein due to certain mutationsHoweverin a substantial fraction of CF patie ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Gene Therapy to Prevent Esophageal Cancer Associated with Aldehyde Dehydrogenase Deficiency
SBC: LEXEO Therapeutics LLC Topic: 400AbstractLEXEO TherapeuticsLLCis an early stage biotechnology company focused on using in vivo gene therapy technologies to treat disorders of unmet medical needLEXEO is developing an in vivo gene therapy strategy as a preventative therapy to protect individuals with aldehyde dehydrogenaseALDHdeficiency from the high risk for esophageal cancerAs the next step in the development paththe goal of this ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health